Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Research & Development (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Research & Development for 12 consecutive years, with $19.5 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 32.64% year-over-year to $19.5 million; the TTM value through Mar 2026 reached $62.8 million, up 25.54%, while the annual FY2025 figure was $58.0 million, 28.66% up from the prior year.
  • Research & Development hit $19.5 million in Q1 2026 for Cartesian Therapeutics, up from $14.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $21.9 million in Q4 2023 and bottomed at $9.7 million in Q1 2024.
  • Average Research & Development over 5 years is $15.7 million, with a median of $14.9 million recorded in 2025.
  • Year-over-year, Research & Development plummeted 48.26% in 2024 and then skyrocketed 50.69% in 2025.
  • Cartesian Therapeutics' Research & Development stood at $19.0 million in 2022, then increased by 15.21% to $21.9 million in 2023, then tumbled by 48.26% to $11.3 million in 2024, then grew by 29.92% to $14.7 million in 2025, then skyrocketed by 32.5% to $19.5 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $19.5 million, $14.7 million, and $13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.